Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2020

01-12-2020 | Acute Respiratory Distress-Syndrome | Research

Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes

Authors: Hongxia Mei, Ying Tao, Tianhao Zhang, Feng Qi

Published in: Journal of Inflammation | Issue 1/2020

Login to get access

Abstract

Background

Acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) are critical life-threatening syndromes characterized by the infiltration of a large number of granulocytes (mainly neutrophils) that lead to an excessive inflammatory response. Emodin (Emo) is a naturally occurring anthraquinone derivative and an active ingredient of Chinese medicine. It is believed to have anti-inflammatory effects. In this study, we examined the impact of Emo on the pulmonary inflammatory response and the granulocytes function in a rat model of lipopolysaccharide (LPS)-induced ALI.

Results

Treatment with Emo protected rat against LPS-induced ALI. Compared to untreated rat, Emo-treated rat exhibited significantly ameliorated lung pathological changes and decreased tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). However, Emo has no protective effect on the rat model of acute lung injury with granulocyte deficiency. In addition, treatment with Emo enhanced the bactericidal capacity of LPS-induced granulocytes via the up-regulation of the ability of granulocytes to phagocytize bacteria and generate neutrophil extracellular traps (NETs). Emo also downregulated the respiratory burst and the expression of reactive oxygen species (ROS) in LPS-stimulated granulocytes, alleviating the damage of granulocytes to surrounding tissues. Finally, Emo can accelerate the resolution of inflammation by promoting apoptosis of granulocytes.

Conclusion

Our results provide the evidence that Emo could ameliorates LPS-induced ALI via its anti-inflammatory action by modulating the function of granulocytes. Emo may be a promising preventive and therapeutic agent in the treatment of ALI.
Literature
1.
2.
Hamid U, Krasnodembskaya A, Fitzgerald M, Shyamsundar M, Kissenpfennig A, Scott C, Lefrancais E, Looney MR, Verghis R, Scott J, Simpson AJ, McNamee J, McAuley DF, O'Kane CM. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax. 2017;72(11):971–80.PubMedPubMedCentralCrossRef
3.
Haohao Dong XTZZ. Structural insight into lipopolysaccharide transport from the gram-negative bacterial inner membrane to the outer membrane. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;11(1862):1461–7.CrossRef
4.
5.
Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015;15(11):692–704.PubMedCrossRef
6.
Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173–82.PubMedCrossRef
7.
Sollberger G, Tilley DO, Zychlinsky A. Neutrophil extracellular traps: the biology of chromatin externalization. Dev Cell. 2018;44(5):542–53.PubMedCrossRef
8.
Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–47.PubMedCrossRef
9.
Liu S, Yue Y, Pan P, Zhang L, Su X, Li H, Li H, Li Y, Dai M, Li Q, Mao Z. IRF-1 intervention in the classical ROS-dependent release of NETs during LPS-induced acute lung injury in mice. Inflammation. 2019;42(1):387–403.PubMedCrossRef
10.
11.
Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates Granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285–94.PubMedCrossRef
12.
Li D, Shao X, Wu J, Yi XX. Noise-induced distributed entanglement in atom-cavity-fiber system. Opt Express. 2017;25(26):33359.CrossRef
13.
14.
Morimoto K, Nishimura K, Miyasaka S, Maeta H, Taniguchi I. The effect of Sivelestat sodium hydrate on severe respiratory failure after thoracic aortic surgery with deep hypothermia. Ann Thorac Cardiovas. 2011;17(4):369–75.CrossRef
15.
Wei W, Lin S, Liu D, Wang Z. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (review). Oncol Rep. 2013;30(6):2555–62.PubMedCrossRef
16.
Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BKH, Ahn KS, Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013;341(2):139–49.PubMedCrossRef
17.
18.
Liew PX, Kubes P. The Neutrophil’s role during health and disease. Physiol Rev. 2019;99(2):1223–48.PubMedCrossRef
19.
Chen Y, Xu Y, Zhang H, Yin J, Fan X, Liu D, Fu H, Wan B. Emodin alleviates jejunum injury in rats with sepsis by inhibiting inflammation response. Biomed Pharmacother. 2016;84:1001–7.PubMedCrossRef
20.
21.
Dong X, Fu J, Yin X, Cao S, Li X, Lin L, Ni J. Emodin: a review of its pharmacology. Toxicity Pharmacokinetics Phytother Res. 2016;30(8):1207–18.PubMedCrossRef
22.
El Benna J, Hurtado Nedelec M, Marzaioli V, Marie JC, Gougerot Pocidalo MA, Dang PMC. Priming of the neutrophil respiratory burst: role in host defense and inflammation. Immunol Rev. 2016;273(1):180–93.PubMedCrossRef
23.
Hurtado-Nedelec M, Makni-Maalej K, Gougerot-Pocidalo M, Dang PM, El-Benna J. Assessment of priming of the human neutrophil respiratory burst. Methods Mole Biol (Clifton, N.J.). 2014;1124:405.CrossRef
24.
Nauseef WM. Identification and quantitation of superoxide anion: essential steps in elucidation of the phagocyte “respiratory burst”. J Immunol. 2014;193(11):5357–8.PubMedCrossRef
25.
Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie. 2008;90(2):227–42.PubMedCrossRef
26.
Meyer-Hoffert U, Wiedow O. Neutrophil serine proteases: mediators of innate immune responses. Curr Opin Hematol. 2011;18(1):19–24.PubMedCrossRef
27.
Muley MM, Krustev E, Reid AR, McDougall JJ. Prophylactic inhibition of neutrophil elastase prevents the development of chronic neuropathic pain in osteoarthritic mice. J Neuroinflamm. 2017;14(1):168.
28.
Polverino E, Rosales-Mayor E, Dale GE, Dembowsky K, Torres A. The role of neutrophil Elastase inhibitors in lung diseases. Chest. 2017;152(2):249–62.PubMedCrossRef
29.
González-Fernández E, Staderini M, Yussof A, Scholefield E, Murray AF, Mount AR, Bradley M. Electrochemical sensing of human neutrophil elastase and polymorphonuclear neutrophil activity. Biosens Bioelectron. 2018;119:209–14.PubMedCrossRef
30.
Kumar H, Choi H, Jo M, Joshi HP, Muttigi M, Bonanomi D, Kim SB, Ban E, Kim A, Lee S, Kim K, Sohn S, Zeng X, Han I. Neutrophil elastase inhibition effectively rescued angiopoietin-1 decrease and inhibits glial scar after spinal cord injury. Acta Neuropathol Commun. 2018;6(1):73.PubMedPubMedCentralCrossRef
31.
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil Elastase, proteinase 3, and CathepsinG as therapeutic targets in human diseases. Pharmacol Rev. 2010;62(4):726–59.PubMedPubMedCentralCrossRef
32.
Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown GD, Papayannopoulos V. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol. 2014;15(11):1017–25.PubMedPubMedCentralCrossRef
33.
Brinkmann VZA. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2017;8(5):577–82.
34.
Hahn J, Knopf J, Maueroder C, Kienhofer D, Leppkes M, Herrmann M. Neutrophils and neutrophil extracellular traps orchestrate initiation and resolution of inflammation. Clin Exp Rheumatol. 2016;34(4 Suppl 98):6–8.PubMed
35.
Metadata
Title
Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes
Authors
Hongxia Mei
Ying Tao
Tianhao Zhang
Feng Qi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2020
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-020-00252-6

Other articles of this Issue 1/2020

Journal of Inflammation 1/2020 Go to the issue

Research

Inhibition of carrageenan-induced dental inflammatory responses owing to decreased TRPV1 activity by Dexmedetomidine

Research

Dendritic cells transduced with glioma-expressed antigen 2 recombinant adenovirus induces specific cytotoxic lymphocyte response and anti-tumor effect in mice

Research

Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury

Research

Urolithin a attenuates IL-1β-induced inflammatory responses and cartilage degradation via inhibiting the MAPK/NF-κB signaling pathways in rat articular chondrocytes

Research

Acupoint application inhibits nerve growth factor and attenuates allergic inflammation in allergic rhinitis model rats

Review

Real-state of autophagy signaling pathway in neurodegenerative disease; focus on multiple sclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits